Clinical Trial

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a) (Lp\[a\]) levels and participants with dyslipidemia.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2025-05-19; most recent amendment 2026-07-10.
Status change: Not Yet Recruiting → Recruiting 2025-06-16
Trial Details
NCT Number NCT06980428
Lead Sponsor AstraZeneca
Conditions Healthy Participants, Dyslipidemia
Enrollment 136 participants
Start Date 2025-05-27
Primary Completion 2026-12-04 (estimated)
Study Completion 2026-12-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-13